NCT01515891已完成1 期
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites Following a Single-dose Oral Administration
Bial - Portela C S.A.1 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2009年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Maximum Plasma Concentration (Cmax)
研究概览
简要总结
To determine the absorption, metabolism and excretion of BIA 9-1067.
详细描述
Monocentre, open, non-placebo-controlled, single-group, single-dose study
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy Caucasian male subjects, 40-55 years of age.
- •Sitting blood pressure and pulse rate within a clinically acceptable range for the purposes of the study, i.e.: BP: 100 - 160 mmHg systolic, 50 - 95 mmHg diastolic and pulse rate: 50 - 100 bpm. Blood pressure and pulse were to be measured after 3 minutes resting in a sitting position.
- •Subject body mass index was to be between 18 and 28 kg/m2
- •Normal 12-lead ECG
- •Ability to communicate well with the investigator and comply with the requirements of the entire study.
- •The subject had given his written informed consent to participate in the study.
排除标准
- •History of serious adverse reactions or hypersensitivity to any drug.
- •Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).
- •History of alcohol or drug abuse in the last 5 years.
- •Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.
- •Need of any prescription medication within 14 days prior to the administration of the drug and/or nonprescription medication within 7 days prior to the administration of the drug.
- •Participation in other clinical trials during the previous month in which an investigational drug or a commercially available drug was tested.
- •Loss of 500 mL blood or more during the 3 month period before the study, e.g., as a donor.
- •Existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the drug, i.e., impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhoea or conditions associated with total or partial obstruction of the urinary tract.
- •Symptoms of a significant somatic or mental illness in the 4 week period preceding drug administration.
- •History of hepatitis B and / or C and / or positive serology results which indicate the presence of hepatitis B and / or C.
- •Positive results from the HIV serology.
- •Clinically significant abnormal laboratory values (as determined by the Principal Investigator) at the screening evaluation, however, liver parameters (SGPT, SGOT) values must be within the normal range.
- •Positive results of the drug screening.
- •Known hypersensitivity to BIA 9-
- •Heavy smokers, i.e., more than 10 cigarettes per day
- •Exposure to artificial ionizing radiation in the last 12 months (e.g., x-ray investigation)
- •Subject who had more than 4 flights (with more than 2 hours flight time) within the last year prior to the administration of the drug.
研究组 & 干预措施
BIA 9-1067
Experimental
90 µCi (3.33 MBq) [14C]-labeled of 100 mg BIA 9-1067 (single-dose).
干预措施: BIA 9-1067 (Drug)
结局指标
主要结局
Maximum Plasma Concentration (Cmax)
时间窗: 24 hours:pre-dose and 1, 1.75, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, and 264 hours post-dose
Whole blood samples for total radioactivity analysis, plasma samples for total radioactivity analysis, and plasma samples for analysis of BIA 9-1067 and its metabolites
次要结局
- Area Under the Plasma-concentration Time Curve With Extrapolation to Infinity (AUC0-∞)(24 hours at the following times: pre-dose and 1, 1.75, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, and 264 hours post-dose)
- Time to Reach Maximum Plasma Concentration (Tmax)(24 hours at the following times: pre-dose and 1, 1.75, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, and 264 hours post-dose)
- Area Under the Plasma-concentration Time Curve Until the Last Quantifiable Sampling Point (AUC0-t)(24 hours at the following times: pre-dose and 1, 1.75, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, and 264 hours post-dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and MetabolitesHypertensionCongestive Heart FailureNCT03014375Bial - Portela C S.A.4
已完成
1 期
Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and MetabolitesParkinson's DiseaseNCT02772614Bial - Portela C S.A.4
已完成
1 期
Absorption, Distribution, Metabolism and Excretion of BIA 5-1058Pulmonary Arterial HypertensionNCT04991181Bial - Portela C S.A.15
已完成
1 期
A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550Healthy VolunteersNCT05101369Incyte Corporation7
已完成
1 期
Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic ImpairmentParkinson's DiseaseNCT02101190Bial - Portela C S.A.16